View by Specialty

Trending

UTI
November 11, 2024
3 min read
Save

WikiGuidelines group publishes first new UTI guidance in 14 years

Rheumatoid Arthritis News

SPONSORED CONTENT
Save
SPONSORED CONTENT
August 09, 2019
2 min read
Save

Sexual dysfunction more common in women with RA, PsA

Sexual dysfunction more common in women with RA, PsA

ORLANDO — Decreased sexual functioning is more common among female patients with rheumatoid arthritis and psoriatic arthritis, which should prompt early screenings for these patient populations, according to study findings presented at the Rheumatology Nurses Society Annual Conference.

SPONSORED CONTENT
August 02, 2019
6 min read
Save

Measles resurgence may pose unique threat to patients with inflammatory diseases

Measles resurgence may pose unique threat to patients with inflammatory diseases

There have been nearly 1,100 measles cases in the United States in the first half of 2019 — more cases of measles than in any year since the disease was declared eliminated in the U.S. in 2000. As of July 25, 30 states have reported cases of measles, with outbreaks currently ongoing in five jurisdictions across the country.

Trending

UTI
November 11, 2024
3 min read
Save

WikiGuidelines group publishes first new UTI guidance in 14 years

SPONSORED CONTENT
July 29, 2019
2 min read
Save

Upadacitinib outperforms adalimumab in methotrexate-refractory RA

Upadacitinib outperforms adalimumab in methotrexate-refractory RA

Upadacitinib, a JAK1 inhibitor, is superior to adalimumab and placebo at improving signs, symptoms and physical function among patients with rheumatoid arthritis who have had an inadequate response to methotrexate, according to data published in Arthritis & Rheumatology.

SPONSORED CONTENT
July 26, 2019
3 min read
Save

FDA approves boxed warning for Xeljanz in UC

The FDA on Friday issued a safety alert and approved new Boxed Warning for the 10-mg, twice-daily dosage of tofacitinib in patients with ulcerative colitis; the warning comes after increased blood clot and death risks were seen in a rheumatoid arthritis trial.

SPONSORED CONTENT
July 24, 2019
1 min read
Save

FDA approves Hadlima, fourth Humira biosimilar

FDA approves Hadlima, fourth Humira biosimilar

The FDA has approved the fourth biosimilar to adalimumab, adalimumab-bwwd, for all eligible indications of the biologic product, according to a company press release.

SPONSORED CONTENT
July 23, 2019
4 min read
Save

Filgotinib improves RA signs, symptoms in DMARD-refractory patients

Filgotinib improves RA signs, symptoms in DMARD-refractory patients

Patients with rheumatoid arthritis who previously had an inadequate response to biologic DMARDs demonstrated improved signs and symptoms after receiving daily doses of filgotinib, according to data published in JAMA.

SPONSORED CONTENT
July 22, 2019
2 min read
Save

Hand with clinically more swollen joints best for ultrasound monitoring in RA

Among patients with rheumatoid arthritis, the hand with more clinically swollen joints is likely to be the best option for monitoring ultrasound activity, and thus best choice for unilateral scoring, according to findings published in Arthritis Research & Therapy.

SPONSORED CONTENT
July 19, 2019
5 min read
Save

Corrona: Leveraging 'Big Data' for Improved Patient Outcomes

Corrona: Leveraging 'Big Data' for Improved Patient Outcomes

Most scientists, by nature and by training, are in one business: Observe a knowledge gap, and fill it. With that in mind, in 2001, the founders of the Consortium of Rheumatology Researchers of North America (Corrona) LLC recognized that there was no database — independent of big pharma — that collected clinical data from both rheumatologists and patients on the safety and efficacy of emerging drug therapies.

SPONSORED CONTENT
July 18, 2019
2 min read
Save

Tocilizumab suitable alternative to TNF inhibitors in DMARD-naïve patients with RA

Tocilizumab suitable alternative to TNF inhibitors in DMARD-naïve patients with RA

Tocilizumab, in monotherapy or in combination with conventional synthetic DMARDs, is an adequate alternative to combination therapy with a TNF inhibitor in patients with rheumatoid arthritis who have not yet been treated with either biological or targeted synthetic DMARDs, according to recent findings in Seminars in Arthritis and Rheumatism.

SPONSORED CONTENT
July 18, 2019
1 min read
Save

IBD risk increases with Enbrel therapy for other autoimmune diseases

Patients receiving Enbrel for inflammatory diseases other than inflammatory bowel disease have an increased risk for a diagnosis of Crohn’s disease or ulcerative colitis, according to study results.

View more
Healio Minute Subscribe to Healio Minute emails You're now subscribed to Healio Minute Emails
Healio Minute Subscribe to Healio Minute emails You're now subscribed to Healio Minute Emails